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Abstract
Objective: To check the ability of microperimetry to detect early reti-
nal damage in rheumatic patients taking hydroxychloroquine (HCQ) and/or
chloroquine (CQ). To describe the microperimetric alterations attributable
to these drugs and their correlation with some clinical variables.
Design: Controlled cross-sectional study.
Participants: Patient group: 209 patients taking HCQ or CQ. Control
group: 204 individuals not under antimalarials. Exclusion criteria: other
diseases that could alter microperimetry.
Methods: An ophthalmic examination and a microperimetry were per-
formed on all individuals. Outcomes: Average threshold (AT), Fixation sta-
bility (FS) and Macular integrity (MI). For the patients, information about
their weight, height, main diagnosis, daily and cumulative dose, creatinine,
bilirubin and transaminases levels were collected. ANOVA, t-tests and a
regression analysis were carried out to detect dierences between groups.
Results: Signicant dierences in microperimetry indexes were detected
between cases and controls, between patients of dierent age groups, and
between patients taking CQ and HCQ. Signicant dierences were also de-
tected in retinal sensitivity between patients overdosed for CQ but not for
those overdosed for HCQ. Daily overdosing per ideal weight alone cannot
explain retinal toxicity, although the eect of cumulative dose in macular
sensibility is signicant to explain both AT and MI.
Conclusions: Microperimetry is an accurate tool for detecting early
macular hyposensibility caused by CQ and HCQ. Microperimetry indexes of
retinal sensibility are worse in elderly patients taking these drugs, and in
2
short stature patients taking CQ. A high cumulative dose is an important
factor in explaining retinal hyposensibility on microperimetry.
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1. Introduction
Chloroquine (CQ) and its analogue, hydroxychloroquine (HCQ) are anti-
malarial drugs that have been used as treatment of various rheumatological
and dermatological diseases including systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA) and chronic discoid lupus.1 However, retinal tox-
icity has been described. Although the risk of toxicity from CQ and HCQ
is low, many thousands of individuals are taking these drugs. After 5 to 7
years of use the prevalence increases to 1%.2 The risk of toxicity depends on
cumulative exposure (a cumulative dose of 1000g of HCQ, which is reached in
7 years with a typical daily dose of 400 mg, and a cumulative dose of 460 g of
CQ, which is reached in 5 years with a typical daily dose of 250 mg). Other
risk factors are renal or liver diseases, underlying retinal disease and age.
The clinical sign of CQ and HCQ toxicity is characterized by a ring of retinal
pigment epithelium depigmentation, often sparing the foveal center, known
as a bull's eye maculopathy. Paracentral scotomas appear before changes
are seen on a fundus examination. Drug use cessation at this stage of early
functional loss might prevent future visual loss, but after maculopathy devel-
ops, cessation of the drug does not show clinical recovery.3 Recommendations
on screening for CQ and HCQ retinopathy are automated visual eld and,
where available, testing with one or more of the recommended objective tests:
spectral domain-OCT (SD-OCT), multifocal electroretinogram (mfERG) or
fundus autouorescence (FAF).4,5 However, visual eld accuracy relies on
patient's cooperation, and the objective procedures are not readily available
in many oces. The goal of screening is to recognize toxicity before a severe
degree of visual eld loss occurs. Nowadays, there is no established a gold
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standard test for screening.
Microperimetry consists in testing perimetry under simultaneous visu-
alization of the fundus. Exact correlation between retinal pathology and
functional alteration is obtained. It allows a precise evaluation of macu-
lar sensitivity, providing an accurate detection of small scotomic areas in
terms of their position, extension and severity in the macular area with a
real-time correction of eye movements.6 Its uses are both clinical and for
research.7,8,9,10,11 In the present study we assess CQ and HCQ toxicity using
microperimetry. Our purpose is to describe the value of microperimetry as
a high sensitivity test for the screening of CQ and HCQ retinopathy. We
study wheather macular sensibility indexes provided by microperimeter are
decreased in our patients with respect to persons not taking antimalarials.
Moreover, we look for the correlation between microperimetry abnormalities
and the main clinical variables inuencing retinal damage.
2. Materials and methods
All patients and controls gave written informed consent to participating
in the study, which was approved by the ethical committee of our hospital
(code 09/046). Moreover, the procedures complied with the tenets of the
Declaration of Helsinki.
A total of 413 individuals have been included in this cross-sectional case-
control study. We studied 209 patients taking CQ and HCQ. In addition,
204 individuals not being treated with antimalarials were included as con-
trols. Controls were chosen from healthy volunteers (57%) and from patients
aected by rheumatic diseases that have never been managed with antimalar-
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ials (43%). In the patient group we obtained data about weight, height, diag-
nosis, daily doses, months under treatment and cumulative dose. A complete
ophthalmological examination was performed in patients and controls which
included visual acuity, biomicroscopy, intraocular pressure and funduscopy.
The presence of corneal drug deposits attributable to CQ and HCQ was
recorded. Data from three consecutive blood analyses (creatinine, bilirubin
and transaminases AST/ALT) were also obtained in order to identify renal
or liver disfunction that could increase CQ and HCQ retinal toxicity. Pa-
tients suering from other diseases that could alter the fundus perimetry
such as glaucoma, gross ametropia, macular drusen, other maculopathies etc
were excluded. Finally, a microperimetry was done using the expert exam
strategy of MAIA microperimeter (CenterVue SpA, Padova Italy). Then we
recorded three indexes provided by the microperimeter: Average threshold
(AT), Fixation stability (FS) and Macular integrity (MI). A stimulus inten-
sity ranged from 0 to 36 dB. A predened grid of 37 points and 30 macular
coverage was used. Threshold sensitivities at each predened point were cal-
culated using a staircase 4-2 strategy. A patient's AT results were compared
with age-adjusted normative data. Two variables in the data set measured
patients' xation stability: FS p1 and FS p2. Both variables measure the
percentage of xation points located within a circle centered on the gravi-
tational center of all xation points. The dierence between them arises on
the diameter of their respective circles, the diameter for FSp2 being greater
than for FSp1. MI is an index of macular health that is calculated using
a neural network multivariate model (see section 4 for a detailed explana-
tion). Best-corrected visual acuity (BCVA) was measured in decimal units
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on a decimal chart. The results were then converted to the logarithm of the
minimum angle of resolution scale (log MAR).
3. Results
All the exams with less than 75% reliability were excluded, nally result-
ing in 200 controls and 194 cases. Table 1 shows the demographics of our
sample. Regarding the patient group, Table 2 shows the main variables col-
lected in a more detailed way. A total of 17 (8:76%) cases were diagnosed as
having a toxic maculopathy (see Table 3) considering clinical and microperi-
metrical ndings: 7 of them were considered as probable maculopathy and 10
(5:15%) as denite toxic maculopathy (see Figure 1). Probable maculopathy
was diagnosed if the patient had a pericentral scotoma with three or more
adjacent points between two and three standard deviations from the normal
average (in yellow in Figure 1) and/or two or more adjacent points with a
sensitivity beyond three standard deviations from the normal average (in or-
ange, red and black in Figure 1). Denite maculopathy was diagnosed if the
patient also had characteristic pigmentary changes of antimalarial toxicity.
Among these 10 patients, 4 had complete bull's eye maculopathy and 6 had
only subtle sectorial depigmentation of the macular area. FS and BCVA were
good (less than log MAR 0.2) in 9 patients having denite maculopathy. The
remaining patient had an advanced bull-eye maculopathy with foveal involve-
ment: unstable xation and BCVA 0.5 log MAR. All 10 patients diagnosed
as having denite maculopathy were women, and all were less than 163 cm
in height. In addition, 3 patients presented corneal drug deposits. All three
were under CQ therapy: one was diagnosed with denite CQ maculopathy
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(cumulative dose = 548 g) and the other was diagnosed as probable CQ mac-
ulopathy (cumulative dose = 274 g). In these two patients, corneal deposits
disappeared a few weeks after stopping antimalarials.
As there were no signicant dierences between AT and MI indexes corre-
sponding to the right and left eye of each patient, from now on, when talking
about AT and MI values, we will refer to the mean value between both eyes
for each patient.
Signicant dierences in AT between cases and controls were detected
(see Table 4). However, MI was higher in controls. This result seemed para-
doxical, because higher MI suggests a greater likelihood of abnormal ndings.
In trying to investigate if a higher MI value in controls could correspond to
a lower xation stability, this variable was also analyzed (Table 4). Never-
theless, no signicant dierences were detected between the mean xation
stability (FSp1 and FSp2) of controls and patients. If age stratication was
done, we could see that MI was signicatively higher in individuals under
60 years-old than in patients, but over 61, patients taking antimalarials had
higher MI than healthy controls (Table 5).
We did not nd signicant dierences in AT or in MI with respect to
liver and renal functional blood analysis. The creatinine, transaminases and
bilirrubine levels of our patients did not show any correlation with macular
hyposensibility on microperimetry.
An ANOVA and a Tukey test were done in order to establish if there
were signicant dierences in microperimetry indexes between patients tak-
ing CQ, HCQ or both drugs. As shown in Table 6, signicant dierences in
retinal sensitivity (AT and MI) were detected between patients taking CQ
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and HCQ, but there were no dierences in the patients that had been man-
aged successively with both drugs with respect to those managed just with
one drug.
As CQ and HCQ are not retained in fatty tissues, we calculated the
daily dose per kg of ideal weight and looked for its relationship with macular
sensibility indexes. Our conclusion was that a daily overdose per ideal weight
alone cannot explain retinal toxicity (Fig. 2). However, using the cut-o
value of toxic doses traditionally considered in medical literature, i.e more
than 3 mg/kg/day for CQ and more than 6:5 mg/kg/day for HCQ, we found
signicant dierences in retinal sensitivity between patients overdosed for CQ
but not for those overdosed for HCQ. We also checked if macular toxicity
was inuenced by our patients' ages. Three age groups were considered:
under 40, between 41 and 60 and over 60 years-old. In our sample, patients
over 60 under treatment with CQ and HCQ presented worse sensitivities
in microperimetry indexes. In fact, when the eect of daily dose per ideal
weight, months under treatment and age were considered together, the most
important variable that inuences macular damage was the patient's age
(adjusted R-squared linear regression=0:6628). Finally, we looked for the
eect of the cumulative dose of antimalarials on macular sensibility. Again,
we found that patients' indexes AT and MI were worse for higher values
of cumulative dose, and that this eect was greater for CQ than for HCQ.
When considering a model including cumulative doses, age, height and age as
explicative covariates, we found that age, height and cumulative dose of CQ
aected AT independently (adjusted R-squared linear regression=0:3187).
Age and cumulative dose of CQ were also related to MI (adjusted R-squared
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linear regression=0:6353).
4. Discussion
The incidence of toxic maculopathy due to CQ and HCQ varies greatly.
More accurate diagnostic methods, or the combination of objective and sub-
jective tests, will allow an earlier diagnosis and probably an increase in the
incidence ratios. It must be taken into account that bull's eye maculopathy
is an advanced sign, and that incidence ratios should also include early cases
of retinal toxicity. These cases are sometimes dicult to diagnose because
pericentral scotomata can be produced by a lot of clinical entities that can
damage the macula in addition to or instead of antimalarials. As retinal
damage will not reverse after stopping the drug, the clinician cannot always
be sure if they were the cause of maculopathy or not.
The appearance of corneal drug deposits in patients under CQ and HCQ
is well known.1 Confocal microscopy has recently been used to detect these
deposits that correlate with high cumulative doses.12 In this study, we found
slit lamp visible deposits in three patients, all three under CQ. Two of them
also presented CQ maculopathy.
In this paper we look for dierences in global indexes provided by mi-
croperimetry between a group of patients taking CQ, HCQ or both, and a
group of untreated persons. We found that the average threshold of retinal
sensitivities at the predetermined points near the foveal center were signica-
tively lower in cases than in controls. This would indicate that antimalarials
induce a global hyposensibility at the macula that does not appear in a sim-
ilar group of population who never took those tablets. All except one of our
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patients had good BCVA and stable xation on microperimetry, and the vast
majority had no pigmentary changes. This corroborates the fact that a loss
of central vision and anatomical changes are advanced signs that should not
be used for screening purposes.4 The other index studied (MI) shows a para-
doxical nding, because for individuals under 60 it is signicatively higher,
i.e more impaired, in controls than in patients. In order to look for some ex-
planation of this result, let us analyze the composition of these two groups.
In all patients one or more conventional macular perimetry were performed
previously because they were included in our clinic's screening program of
antimalarial toxicity. The control group included people without any eye
disease, so they never underwent visual eld testing. It is possible that the
learning eect explains in part why controls have worse MI than patients.
Test-retest reliability of macular fundus perimetry was checked by Chen et
al.13 MI uses a neural network multivariate model that includes age, average
threshold value, a measure of points with threshold below 25 dB and all mea-
sured threshold values. MI is a numerical value that describes the likelihood
that a patient's responses are normal when compared to age-adjusted norma-
tive data. The neural network has been trained on normal and pathological
examinations (age-related macular degeneration). With respect to normative
data used in the elaboration of the MAIA neural network (Smolek et al, Neu-
ral Network Algorithms for a Device to Measure Macular Visual Sensitivity.
Scientic poster. ARVO Meeting 2010), our patients and controls had lower
AT. A neural network is a classier where the aforementioned inputs are used
to obtain that likelihood. Unlike other classiers such as the classical linear
discriminant, neural networks are black boxes, and you cannot know which
11
variables are the most discriminative. Furthermore, care should be taken
with the training to avoid overlearning, i. e. a good performance with the
training sample but with a poor generalization with unseen samples. The
images of our young controls with high MI were revised and we found that
they had a threshold below 25dB in a few points, which probably produced
those high MI despite having good average threshold. Furthermore, in those
cases, the MI dierence between both eyes was high, which was not so fre-
quent among the patients. Larger prospective studies must be done in order
to validate MI as a good index for evaluating other diseases distinct from
age-related maculopathy.
In our sample, mean age and cumulative dose are signicatively higher
for patients under CQ and both drugs than in patients that are treated with
HCQ only. In Spain, HQC was not available until 2002. Moreover, the
rst commercially available presentation of HCQ presented some problems
of tolerance,14 and some patients were either switched back to CQ or their
physicians postponed the use of HCQ until this problem was solved some
years later. This is why in our sample patients under HCQ are younger
and their cumulative doses are smaller than those treated with CQ. This
bias can explain why we found a low incidence of maculopathy in patients
taking just HCQ, even though a greater retinal toxicity for CQ has largely
been evidenced.15 However, it has been considered that the increased toxicity
rates of CQ could be due to pill size for chloroquine (250 mg), which makes
overdosing much easier than with HCQ.16 In fact, all patients measuring less
than 160 cm would be at risk of CQ toxicity because of overdosing.2 In our
study, 80% of patients diagnosed as having toxic maculopathy were overdosed
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for CQ, and all of them were of short stature.
As anatomical changes seen on funduscopy appear late, new imaging tech-
niques have been used to improve early diagnosis, such as fundus autou-
orescence and sprectral-domain OCT. Electrophysiological tests of retinal
function, mainly mfERG, is also considered in early diagnosis or as an addi-
tional tool to conrm doubtful cases.17 However, in a recent paper,18 mfERG
failed to detect as much as approximately 28% of individuals with hydrox-
ychloroquine retinal toxicity. False negatives appear to be even higher for
SD-OCT than for mfERG testing. Evidence about the usefulness of FAF in
early diagnosis is lacking.18,19 Macular perimetry, funduscopic examination
and photography continue to provide the highest yields of early cases.17 It
has been recently considered that revised guidelines,4 emphasizing mfERG,
SD-OCT or FAF, raised screening cost without improving case detection.16
We believe that fundus microperimetry provides more detailed information
about retinal sensibility at the macular area and gives the clinician a precise
correlation with anatomical changes. Our results indicate that microperime-
try is a very good test to detect early and subtle functional impairment
caused by CQ and HCQ.
CQ and HCQ are eective drugs in the management of severe rheumatic
disease, but in order to avoid retinal damage, dosage must be careful, par-
ticularly in short patients who are expected to be treated for many years.
Advanced age is an important risk factor for toxicity.17 To the best of our
knowledge, this is the rst study that uses microperimetry as a screening
test for retinal toxicity because of antimalarials. In fact, this is the rst work
that uses microperimetry in a sample of more than 200 individuals.
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5. Conclusions
Microperimetry is an accurate tool for detecting early macular damage
associated with CQ and HCQ therapy. Patients taking CQ, HCQ or both
show reduced threshold retinal sensibility in the macular area. High HCQ
and/or CQ cumulative doses, advanced age, daily CQ overdosing per ideal
weight, and short stature are independently associated with worse macu-
lar indexes on microperimetry. There are several limitations to the present
study. Larger prospective studies must be carried out in order to conrm
the presence of macular hyposensibility over time. Future directions will be
the description of spatial localization and characterization of early central
scotomas induced by CQ and HCQ.
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Table 1: Description of the database.
Controls Cases p-value
Sex:(% Female) 84:00% 80:42% 0.42
Age: average  sd 53:74 13:37 51:24 15:13 0:08
Weight (in Kg): average  sd { 70:15 15:35 {
Height (in cm): average  sd { 159:71 12:98 {
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Table 2: Description of the group of patients. Diagnosis acronyms: systemic lupus ery-
thematosus (SLE), rheumatoid arthritis (RA), other: undierentiated arthritis, cutaneous
diseases. Overdosed : HCQ = patients receiving more than 6,5 mg/Kg ideal weight/day;
CQ = patients receiving more than 3 mg/Kg ideal weight/day. CQ ! HCQ = Patients
rst on CQ and switched to HCQ over the evolution of the disease. According to the
characteristics of the dierent variables, this table shows either the mean  sd values or
the respective counts and percentages.
HCQ CQ CQ ! HCQ p-value
n(%) 130 (67:01%) 30 (15:46%) 34 (17:52%)
BCVA (LogMAR, mean) 0.06  0.09 0.10  0.13 0.12  0.21 0.03
Diagnosis:
SLE 64 (68:81%) 10 (10:75%) 19(20:43%)
RA 33(55:00%) 15 (25:00%) 12 (20:00%)
Other 32 (84:21%) 4 (10:53%) 2 (5:26%)
Duration of theraphy (months) 38.29  38.88 103.66  63.88 121.55  59.31 < 0:001
Cum. HCQ dosis 357.61 381.04 0 503.23  445.46 0:09
Cum. CQ dosis 0 733.53  432.96 475.76 411.97 0:02
Overdosed (n (%)) 22 (16:92%) 25 (83.33%) 7 (20:58%) < 0:001
AST 21.72  8.26 22.24  7.67 22.94  8.73 0.73
ALT 21.37  14.58 20.41  7.19 22.68  17.08 0.81
Bilirrubin 0.49  0.34 0.56  0.32 0.43  0.19 0.31
Creatinine 0.79 0.23 0.81  0.16 0.89  0.46 0.17
Corneal Drug Deposits (n) 0 3 0
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Table 3: Characteristics of patients with toxic maculopathy.
HCQ CQ CQ ! HCQ Global
n(%) 2 10 5 17
Probable maculopathy 1 4 2 7
Denite maculopathy 1 6 3 10
Age 41.009.89 57.00 11.56 60.6020.21 56.1714.78
Cum HCQ dosis 200.5 180.31 0 251.8  308.24 207.50 257.88
Cum CQ dosis 0 648.10  252.13 689.40 763.23 661.87  455.75
Overdosed (n (%)) 1 (50:00%) 8 (80:00%) 2 (40:00%) 11 (64:70%)
Deposits (n (%)) 0 2 (20%) 0 2 (11:76%)
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Figure 1: Interpolation maps of microperimetries corresponding to: (left) a patient diag-
nosed as denite maculopathy with stable xation and good central responses but severe
pericentral hyposensitivity with an absolute scotoma; (right) a patient diagnosed as prob-
able maculopathy with stable xation and good central sensitivity but nasal pericentral
scotoma.
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Table 4: Dierences between controls and cases in FS, AT and MI (sd denotes standard
deviation).
Global Cases Controls p-value
Cases vs Controls
mean sd mean  sd mean  sd
Mean AT 26.83  2.27 26.52  2.64 27.12  1.81 0.0092
Mean MI 43.56  34.02 32.72 34.33 54.07  30.29 0
Mean FS p1 90.83  11.57 89.9  12.58 91.83 10.42 0.0827
Mean FS p2 97.18  5.82 96.93  5.98 97.42 5.67 0.4062
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Table 5: Comparison of MI and FSp1 mean values between cases and controls for dierent
ages.
Age
 40 (40  60] > 60 p-value
MI Cases 5.45  9.57 21.75 23.26 73.61  23.61 < 0:0001
Controls 26.38 26.31 50.8  26.12 74.77 23.11 < 0:0001
p-value < 0:0001 < 0:0001 0:7842
FS p1 Cases 93.68  6.74 90.87 9.68 84.66  17.83 0:0003
Controls 92.66 12.01 92.45 8.53 90.42  11.92 0:4148
p-value 0:6406 0:2521 0:0402
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Table 6: Dierences between AT and MI mean values depending on the drug.
HCQ CQ CQ ! HCQ p-value
Mean AT 26.902.08 24.96 3.61 26.443.06 0.0011
Mean MI 27.7831.26 49.97 38.18 36.3637.56 0.0042
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Figure 2: Daily dose per Kg of ideal weight versus (a) average threshold and (b) macular
integrity.
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